| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | As monotherapy for the maintenance treatment of adult patients with PSR high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 19/09/2018 |
| Rapid review completed | 01/10/2018 |
| Rapid review outcome | The NCPE recommend a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 16/10/2018 |
| Pre-submission consultation with Applicant | 26/11/2018 |
| Full submission received from Applicant | 28/06/2019 |
| Preliminary review sent to Applicant | 30/09/2019 |
| NCPE assessment re-commenced | 25/10/2019 |
| Factual accuracy sent to Applicant | 02/12/2019 |
| NCPE assessment re-commenced | 12/12/2019 |
| NCPE assessment completed | 04/02/2020 |
| NCPE assessment outcome | The NCPE recommends that olaparib (Lynparza®), for this indication, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
